Scientists and company- builders, creating the medicines of the 21st century

James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Bio. He also holds multiple board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.

Juliette Han is the Chief Financial Officer & Chief Operating Officer at Cambrian Bio. Han was previously the Chief of Staff at Two Sigma Private Investments Group, the Private Investments division of the hedge fund Two Sigma. Prior to Two Sigma, Han was a Chief Operating Officer of People - Human Resources Operations at the hedge fund Citadel, where she led strategic thinking behind performance and teams. Prior to Citadel, Han was Chief of Staff for McKinsey New Ventures at McKinsey & Company and a strategy and commercialization consultant in the New York office’s pharmaceutical practice. Han holds a Ph.D. in Neuroscience from Harvard University, as well as an M.S. in Physiological Sciences and B.S. in Neuroscience and Physiological Science, both from UCLA. She serves on the alumni advisory council of Harvard Medical School, Division of Medical Sciences and an academic advisor. She is also an adjunct professor at Columbia Business School.

Teri Champ is the General Counsel at Cambrian Bio. She was previously General Counsel to CancerLinQ, a big data initiative collecting and analyzing data from cancer patients at practices nationwide to improve the quality of cancer care. She served as Senior Counsel to the American Society of Clinical Oncology (ASCO), the world’s leading professional organization for physicians and oncology professionals caring for people with cancer, where she focused on strategic transactions, intellectual property, and data privacy. Previously, Teri served as Senior Counsel with Foley & Lardner LLP, practicing corporate and business law with an emphasis on M&A, securities, licensing, and corporate governance. She was on the Board at AIM Health Institute, a non-profit group focusing on integrative medicine and access to care by underserved communities. Teri holds a J.D. from the University of Michigan School of Law, and a B.S. in Political Science from Vassar College.

Mark Nuttall is the Executive Vice President of Business Development at Cambrian Bio. He was previously Chief Business Officer for Kintai Therapeutics/Senda Biosciences, a Flagship Pioneering company, and Kymera Therapeutics (KYMR). Before moving to biotech, Mark held increasingly senior roles in business development functions at several large pharmaceutical companies. He was Vice President and Head of Business Development & Licensing for core therapeutic franchises at Sanofi Genzyme: immunology, inflammation and multiple sclerosis; at Johnson & Johnson, he led neuroscience business development and was responsible for leading a team that transformed J&J’s CNS portfolio. Mark began his career in the healthcare industry in R&D at GlaxoSmithKline and AstraZeneca. He has a B.Sc. in biochemistry from the University College of Wales in Cardiff and a Ph.D. in molecular and cell biology from the University of Aberdeen, Scotland.

Georg C. Terstappen is the Executive Vice President of Drug Discovery at Cambrian Bio. He has 30 years of experience in big pharma/biotech, holding R&D leadership positions at Bayer, GW/GSK, and Abbott/AbbVie –most recently as Head of Preclinical CNS Drug Development with GSK. Georg was also Co-Founder/CSO of Siena Biotech and CSO of OxStem (a University of Oxford spin-out company). In addition, Georg has led EU R&D framework organizations as Vice-Chair of the Innovative Medicines Strategy group in the context of EFPIA and IMI. He was also adjunct professor/visiting scientist at several universities, including the University of Oxford, and leader of European-wide research programs funded by the EC. Georg has published 90 scientific articles and is inventor/co-inventor of 15 patents. He has a first-class honors degree in Biology and conducted research at the Max-Planck-Institute and the Federal Research Centre Juelich, for which he has received a PhD in natural sciences.

Dennis Yamashita is the Executive Vice President of Chemistry at Cambrian Bio. He is an exceptional drug hunter and medicinal chemist with 30 years in pharmaceutical and biotech drug discovery. Dennis was VP, Medicinal Chemistry at Axial Therapeutics; VP, Drug Discovery at ORIC; and VP, Chemistry at Trevena, a startup founded by Nobel laureate Robert Lefkowitz. At Trevena, he co-invented OLINVYK (oliceridine), an FDA-approved analgesic for the treatment of post surgical pain. Dennis spent 20 years at GSK, most recently leading drug discovery research collaborations with premier academic institutions, as well as internal drug discovery projects in oncology, osteoarthritis, osteoporosis, and immunology disease areas. Dennis has a B.S. in Chemistry from MIT and Ph.D. in Organic Chemistry from Yale. He mentors MIT postdoc scientists and volunteers at the MIT Sandbox, an entrepreneurship program for MIT students that aims to move ideas from concept to societal impacts.

Ruth Thieroff-Ekerdt, MD, serves as Executive Vice President Clinical Development at Cambrian Bio. Prior to joining Cambrian, she was Chief Medical Officer at Sojournix, and Acting CMO/Scientific Advisor at Organon. She also served as Chief Medical Officer at Aptalis, Strongbridge, Kaleido and held R&D positions of increasing responsibility at Bayer. She graduated as MD and Dr. med. from the Free University Berlin and specialized in Pharmacology and Clinical Pharmacology. She has over 30 years of experience in pharmaceutical R&D at all stages of discovery, development, and commercialization, with a successful track record of leading translational and development programs, submissions, and product launches in EU and US in various therapeutic areas and technologies. She also served as expert in the European Innovative Medicine Initiative and on the Scientific Advisory Board for Chr. Hansen. Ruth has published 28 scientific articles and conference contributions and is inventor/co-inventor of 31 patents.

Christian Angermayer is the Chairman and Co-Founder of Cambrian Bio. A serial entrepreneur and investor, Christian has raised over $1.6B for his portfolio companies. He was co-founder of Ribopharma, a German biotech company pioneering RNAi (today Alnylam, $9B market cap). Via his family office Apeiron Investment Group, he has invested in many companies in the life sciences and fintech sectors and has been party to over 40 successful M&As and IPOs. He is a founder and investor in another biotech holding company, ATAI Life Sciences, focused on neuropharmacology. In 2017, the Swiss-German business magazine BILANZ ranked Christian in the top 10 most important German tech investors. Christian has produced 14 feature films and was named an emerging global leader by the World Economic Forum and the Milken Institute.

Maryanna Saenko currently serves as Co-Founder and Partner at Future Ventures, a firm she launched with Steve Jurvetson focused on disruptive technology such as commercial space exploration, deep learning, quantum computing, robotics, AI, blockchain, sustainable transportation, synthetic biology and clean meat. Previously she was a Principal at Khosla Ventures, and prior to that a Senior Associate at DFJ, where she worked with Steve to focus on frontier technology investments. She was also an investment partner at Airbus Ventures, the early-stage investment group of Airbus, where she led a series of venture investments strategically aligned with Airbus’ future-of-aerospace initiatives. She started her career as a research engineer at Cabot Corporation. Maryanna is a frequent industry speaker on the future of automation and has appeared at Robobusiness, Unmanned Systems Institute, and CES. Maryanna graduated from Carnegie Mellon University with a BS in Biomedical Engineering and a BS and MS in Materials Science and Engineering.

Brenton L. Saunders is currently the Executive Chairman of The Beauty Health Company. Before joining The Beauty Health Company, he was Chairman, President and CEO of Allergan, having previously served as CEO and President, and Director of Forest Laboratories (prior to its acquisition by Allergan). Prior to that, he served as CEO of Bausch + Lomb, a leading global eye health company. Brent also held a number of leadership positions at Schering-Plough, including President of Global Consumer Health Care, and was named Head of Integration for the company’s merger with Merck & Co. and its acquisition of Organon BioSciences. Before joining Schering-Plough, he was a Partner and Head of Compliance Business Advisory at PwC, as well as Chief Risk Officer at Coventry Health Care and Senior Vice President of Compliance, Legal and Regulatory at Home Care Corporation of America. He  began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. Brent also  serves on the Board of Directors of Cisco Systems and BridgeBio and is a member of the Business Council.

Paul Farr co-founded and co-leads Anthos Capital, a Santa Monica based private equity firm. Before Anthos, he was an investor with Summit Partners and an investment banker with Goldman Sachs & Co. Paul received his B.Com. from McGill University and his M.B.A. from Stanford University. Paul serves on numerous corporate and charitable boards.

R. Martin Chavez is a Partner and Vice Chairman of Sixth Street Partners, where he works on research and development; diversity, equity, and inclusion; the sourcing engine; and the More Than Capital business, driving deeper engagement with the portfolio companies. Before joining Sixth Street, he served in a variety of senior roles at Goldman Sachs, including Chief Information Officer, Chief Financial Officer, and Global Co-Head of the Securities (now Global Markets) Division. He was also a partner and member of the Goldman Sachs management committee. Chavez co-founded San Francisco start-up Quorum Software Systems, and was later CEO of Kiodex, a risk management systems company that was later acquired by SunGard Data Systems. He holds an A.B. magna cum laude in Biochemical Sciences and a S.M. in Computer Science from Harvard, as well as a Ph.D. in Medical Information Sciences from Stanford.

Steve Jurvetson is an early-stage venture capitalist with a focus on founder-led, mission-driven companies at the cutting edge of disruptive technology and new industry formation. Steve was an early VC investor in SpaceX, Tesla, Planet, Memphis Meats, Hotmail, and the deep learning companies Mythic and Nervana. He also led founding investments in five companies that went public in successful IPOs and several others that became billion-dollar acquisitions. His board seats include SpaceX and Tesla. Before co-founding Future Ventures and Draper Fisher Jurvetson, Steve was an R&D Engineer at Hewlett-Packard. He also worked in product marketing at Apple and NeXT and management consulting with Bain & Company. He completed his undergraduate Electrical Engineering degree at Stanford in 2.5 years, graduating #1 in his class, and went on to earn a MSEE and MBA from Stanford. In 2017, Steve received the Visionary Award from SV Forum. In 2016, President Barack Obama appointed Steve as a Presidential Ambassador for Global Entrepreneurship.

Jessica Ainscough is the Senior Director of Clinical Operations for Cambrian Bio. Jessica brings over 17 years of experience in the industry as a dedicated clinical operations and quality management leader. Jessica has held leadership roles in clinical operations at Epizyme, Kadmon Holdings and ICON and in compliance management at Tesaro and Beth Israel Deaconess Medical Center in which she developed risk management programs. Jessica has been at the forefront of clinical operations design and development and strategically bringing early stage clinical assets through to FDA approval.

Rosa Argyropoulos serves as Senior Director of Global Corporate Communications at Cambrian Bio. Prior to joining Cambrian, she held positions of increasing responsibility at Flagship Pioneering, Takeda Pharmaceuticals and Otsuka Pharmaceuticals, where she expanded the global reach and uplifted executives’ level of positive exposure while enhancing the company’s image. Before her decade-long work in the biopharma / biotech world, she was a journalist reporting on both local and international stories. Argyropoulos earned her Master of Journalism from University of California, Berkley and was awarded the I.F. Stone Prize, recognizing excellence in human rights reporting. She earned her Bachelor of Artsin Communications from University of Massachusetts, Amherst. Argyropoulos has lived and worked in Boston, New York, San Francisco, Tokyo and Hong Kong.

Sreenivas Avula is Director of CMC Biologics at Cambrian Bio. He has over 11 years of academic and 15 years of biopharma industry/GMP experience in the field of biotherapeutics development. Prior to joining Cambrian he managed CMC analytical R&D at IAVI, comprising broadly neutralizing monoclonal antibodies (bnAbs), spike pre-fused-protein vaccine candidates, and ScFv fusion proteins and nanoparticles. Previously, Sreenivas has held multiple roles at big biopharma companies comprising Bristol Myers Squibb, Eli Lilly, Genzyme, Janssen and at a leading CDMO, where he was involved in late phase to commercial development of biologics. Sreenivas has a MSc in Biochemistry from Sri Krishnadevaraya University and received his PhD in Biochemistry from the Indian Institute of Science. His published postdoctoral research work was conducted at the Weizmann Institute, Carnegie Mellon University, Rutgers University, and the University of Alberta.

Alexandra Baranowski is a Business Operations Manager at Cambrian Bio. She was previously an investment analyst at London-based Playfair Capital, focusing on seed and pre-seed deals. Prior to joining Playfair, she was Editorial Associate for the All-Party Parliamentary Group for Longevity, working on the strategy for extending healthspan in the UK. She has spent time at CBPartners and Solon Management Consulting, working across healthcare and TMT projects. Alexandra studied Natural Sciences at Cambridge University and holds a B.A. in Genetics and MSc in Systems Biology. She is currently part of Harvard Business School’s 2+2 deferred MBA Program cohort.

Nicola Boekstein serves as Director of Corporate Strategy at Cambrian Bio. Prior to joining Cambrian, she was Manager in the IQVIA Financial Institutes Consulting Group, providing life sciences advisory services to investors and biopharma clients. She has also worked as Associate Director, Portfolio Management in the Business Development team at BenevolentAI, focusing on corporate strategy and development,and as a Strategy Consultant for IMS Consulting Group (now IQVIA). She earned her Master of Science in International Health Policy and Economics from the London School of Economics, and her Bachelor of Artsin Natural Sciences, specializing in Genetics, from University of Cambridge.

Diana is a scientist and R&D cross-functional, global program leader with strategic and tactical experience in both research and clinical development programs, preclinical to phase 3. She has experience with strategic and operational planning, project tracking, risk identification, cost oversight, budget forecasting, and resource management. Experience facilitating cross-functional teams to develop project development scenarios and to manage conflict resolution, and issue escalation. She has held strategic and operational responsibilities for senior leader stakeholder and external partner/vendor oversight at Sanofi and Takeda. Diana started her career at Schering-Plough in BioTechnology Development following an industrial post-doc.  She has a PhD in Biochemistry, Molecular Biology, and Cell Biology from Northwestern University and a AB in Biochemistry from Mount Holyoke College.

Veronica Camacho is the Executive Assistant to the CFO/COO at Cambrian Bio. Prior to joining Cambrian, Veronica was the Program Coordinator for the Respiratory Department at New York Presbyterian Hospital where she supported the Director and 85 therapists during and after COVID. She previously served as the Operations Coordinator at Douglas Elliman, she led and managed the full cycle of every project as well as managing the multi-dollar listings. She understands the challenges and has developed solutions for her teams. The feeling of watching others succeed and knowing she had a part in it is her incentive.

Catherine Chung is the Executive Assistant to the CEO at Cambrian Bio. Catherine joined Cambrian with nearly a decade of experience supporting CEOs and other C-level executives. Before joining Cambrian, she served as a Business Development Manager at PaperChef and an Operations Manager at Quentin Road Ventures Management, where she drove organizational change through process development and implementation across departments while simultaneously providing coordination and logistical support to the CEO. Catherine received her bachelor’s degree in Business Administration from Baruch College, Zicklin School of Business.

Sara Cole serves as Business Operations Manager at Cambrian Bio. Prior to joining Cambrian, Sara worked as a Life Sciences Strategy Consultant at IQVIA, a large healthcare data science company and contract research organization, providing strategy and advisory services to guide clients in making high-level decisions in the life sciences field. She has also worked at Corning Incorporated, a global innovator in materials science, as a research technician across multiple business units. Cole completed her MBA in the Health Sector Management Program at Boston University and her BS in Medicinal Chemistry from the University at Buffalo. She also serves as a board member for Cure Rare Disease, a nonprofit biotech.

Stephanie Erjavec serves as Business Operations Manager at Cambrian Bio. Prior to joining Cambrian, she was a consultant at IQVIA where she focused on pricing & market access solutions for various biopharmaceutical assets. Erjavec earned her PhD in Genetics & Development from Columbia University and Bachelor of Science degree from University of California, Santa Barbara.

Andy Feng is a Director of Portfolio Analysis at Cambrian Bio. Before joining Cambrian, he was part of the management team at Synfioo, a Berlin-based machine learning company, where he focused on finance, strategy, and operations. Prior to Synfioo, Andy worked as an Analyst at Apollo Ventures, the first global longevity-focused venture capital firm. He has also served as Head of Finance and Operations at Xanadu, a Toronto-based photonic quantum computing company, and began his career in the Financial Institutions Audit Group at KPMG. Andy holds a BBA from the Schulich School of Business at York University.

Lorna Fiedler is a Director of Research & Development Project Management at Cambrian Bio. She has over 20 years’ experience in research and drug discovery including leadership positions across several therapeutic areas. Lorna is passionate about translating innovative science into patient benefit and has an established track record in leading and managing cross-functional teams. Prior to joining Cambrian, Lorna was Principal Scientist and Program Manager at e-therapeutics, where she was responsible for assessment and development of the company’s first RNAi pipeline program. She was previously Associate Director for Research at Oxstem, an Oxford University spin-out focused on regenerative medicine. Lorna received her PhD from Cardiff University, UK and has held postdoctoral positions at University College London and Imperial College London, UK, and Duke-NUS Medical School in Singapore. Her research has been published in leading journals and resulted in a patented cardioprotective small molecule therapeutic featured in Fierce Biotech, for which she is a named inventor. Lorna is also an Associate Editor for Bioscience Reports.

Adrienne Hallett is the Vice President for Global Policy at Cambrian Bio. She has 25 years of health policy experience at the highest levels of the US government. Hallett previously served as the Associate Director for Legislative Policy & Analysis for the National Institutes of Health, the world’s largest funder of biomedical research. She briefly served as an advisor to the Biden White House on the establishment of ARPA-H and the launch of a national initiative to eliminate Hepatitis C. Prior to that, she served on the Appropriations Committee of the US Senate as a lead negotiator for funding of public health and research programs. She drafted dozens of US health laws, including portions of the Affordable Care Act relating to prevention policies and programs. She holds a Master’s in Theological Studies from Vanderbilt Divinity School with a concentration in Ethics.

Zhen Huang Cao serves as Director of Business Development at Cambrian Bio. Prior to joining Cambrian, she was Associate Director of Business Development at Otsuka Pharmaceuticals. She has also worked as a Consultant at Alacrita Consulting, was a Helmsley Postdoctoral Fellow at Rockefeller University, and worked at The Rockefeller University’s Office of Technology Transfer. Huang Cao earned her PhD in Pharmacology from University of Cambridge, and her Bachelors of Arts in Biology and Psychology from University of Chicago.

Vrej Jubian is a Director, API Manufacturing and Drug Product, CMC. With over 25 years experience in pharmaceutical, biotech and chemical industries, he brings expertise in chemical development of small organic molecules from the discovery stage to the clinic.  Prior to joining Cambrian, He served in the Business Management group at Thermo Fisher’s API drug substance division providing technical assessments and solutions for clients looking to develop their clinical candidates.  Before Thermo Fisher, he worked as the CMC Manager for Synaptic Pharmaceuticals and subsequently as a Principal Scientist for Lundbeck.  He managed outsourcing activities for development programs and internal medchem projects. He also headed a scale-up lab and provided leadership in drug discovery projects where his group identified several drug development candidates targeting novel GPCRs for CNS therapeutics.  Vrej received his PhD in organic chemistry from McGill University (Montreal, Canada) and completed his postdoctoral training at University of Pittsburgh.

‍

Caroline Kavanagh serves as Human Resources Manager at Cambrian Bio. Prior to joining Cambrian, Caroline was the Benefits & Compliance Specialist at Aquent. She has also worked as a Clinical Research Assistant and Coordinator at the Massachusetts General Hospital. Kavanagh earned her MBA in Risk Management from the Greenberg School of Risk Management at St. John's University and a Bachelor of Science in Health Policy & Management from Providence College.

Margaret Kurtz is the Director of People and Culture at Cambrian Bio. Prior to joining Cambrian, Margaret served as the Director of Talent and Recruitment for the Rutgers University Foundation, the Foundation created to inspire philanthropic support enabling Rutgers, the state university of New Jersey, to transform lives. In her role, Margaret oversaw recruitment and DE&I, while also supporting all areas of talent management and organizational growth strategy. Prior to her time at Rutgers, Margaret worked at DRG Executive Search and the United Nations Foundation in their recruiting functions. Margaret holds a B.A. in Psychology from the George Washington University.

Wenjie Luo serves as Business Operations Manager at Cambrian Bio. Prior to joining Cambrian, she was the Senior Business Development Associate at Cresilon, a biotechnology startup, where she led numerous initiatives to better the company's business development and operations, including securing a $3M non-dilutive capital grant to expand the company's regional footprint. She has also served as a researcher at academic laboratories at Columbia and Cornell Universities. Luo earned her Master of Science in Biomedical Engineering from Columbia University and Bachelor of Science in Biological Engineering from Cornell University.

Jasmine Malshe is a Sr. Business Operations Manager at Cambrian Bio. She has over 12 years of operations experience in the Pharma/biotech and medical device industry. Jasmine is experienced in processes improvements, continuous improvement, establishing new processes related to different aspects of operations. Prior to joining Cambrian, Jasmine was Sr. Advance Operations Manager at Hologic Inc, a medical device company focusing and leading in women’s health. There, she led a team of Engineers and Project managers to establish framework and process to ensure successful launch of New Products into manufacturing and market. In one of her prior roles at Stryker Orthopedics she established a new department from scratch for end-to-end manufacturing of custom Implants for cancer patients. Jasmine holds a M.S. in Biotechnology from University at Buffalo and B.S. in Pharmacy from University of Pune, India. ​

Nicole Martucci, PhD., serves as a Venture Associate at Cambrian Bio. Prior to joining Cambrian, Nicole earned her PhD in Cellular and Molecular Pathology from the University of Pittsburgh School of Medicine. Simultaneously while working on her PhD, Nicole was a consultant, project manager, and CEO of the student led non-profit consulting company, Fourth River Solutions, based out of Pittsburgh. Nicole also received her bachelors degree in Biomedical Engineering from Binghamton University.

Emily Mason serves as People Strategist, Pipeline Companies at Cambrian Bio. Prior to joining Cambrian, Emily was the Human Resources Program Manager at Catamaran Bio, Inc. She has also worked as the Human Resources Operations & Administrative Manager at resTORbio, Inc. Mason earned a Bachelor of Arts in Management & Financial Operations from Simmons College School of Management.

Simon Mazza-Lunn is a Director of Research & Development Project Management at Cambrian Bio. Prior to joining Cambrian, he served as a Project Manager at Harrington Discovery Institute (HDI), providing project management support to Harrington scholars and working closely with the Therapeutics Development Team strategic advisors to accelerate discovery and development of funded programs. Before HDI, Simon was Director of Laboratory Operations at Renovo Neural, a CRO focused on pre-clinical efficacy studies for multiple sclerosis. While at Renovo, Simon managed all client-related studies, as well as directing internal research and development efforts. He received his PhD from the University of Dundee, UK, and completed his postdoctoral training at the University of Michigan. While at the University of Michigan, he established a biobank of primary patient tissues to help researchers develop future therapies.

Brendan Murphy is a former patent litigator from Fish & Richardson. He also has experience as a contracts attorney at Dynatrace, Inc. and most recently managing negotiations for a breadth of agreements as Associate Director within the Office of Clinical Research at University of Massachusetts Medical School.

Claire O’Brien is a Senior Director of Research & Development Project Management at Cambrian Bio. She has 30 years of experience in developing medicines at Ipsen, GlaxoSmithKline (including Glaxo Wellcome and Glaxo Group Research), and in biotech, an in-depth knowledge of medicine development, and a track record in leading global, matrixed teams to advance programs through discovery, development, and launch. After earning a degree in chemistry at Kingston University London, she spent ten years in formulation and analytical development, then moved into cross-functional project leadership, working in multiple disease areas and with teams across US, EU, China, and Japan. Her deep interest in the development and growth of talent has been a theme throughout her career, and she has been coaching for 15 years with a particular interest in coaching scientists to lead.

Bhushan Pant serves as the Technical Product Manager at Cambrian Bio. Previously, he worked as a Senior Product Manager at Chegg, building Chegg’s Content Knowledge Graph and driving Personalization strategy. Prior to Chegg, he headed the product development team at Egregore Labs. Pant graduated from College of Technology, Pantnagar, with an Engineering degree in Information Technology and also holds two master’s degrees, a master’s in management from Delhi School of Management, DCE and a master’s in technology from Universidad Politécnica de Madrid.

Claudia Pareja serves as Digital and Social Media Associate at Cambrian Bio. Prior to joining Cambrian, she was a Social Media Coordinator at Capstone Production. She has also worked similar roles in marketing where she modernized brands’ content and developed an effective multi-channel strategy to capture, engage and retain new audiences. Pareja earned her a BA in Writing and Web Design from Trinity Christian College.

Mary Phelan is the Controller at Cambrian Bio. She is a senior-level CPA with over 20 years of hand-on accounting and financial reporting experience, including Controller positions at multiple growing biotechs where she helped to build and manage all accounting operations as well as set up financial reporting for IPO readiness, due diligence, GAAP and SEC filings, corporate governance, budget to actual analysis, equity and debt financings with complicated financial instruments. Phelan earned her BBA from Pace University's Lubin School of Business.‌

Matthew Piva serves as Venture Director at Cambrian Bio. Prior to joining Cambrian, he was an Engagement Manager at McKinsey & Company. He has also served as an Innovation Advisor for the Tsai Center for Innovative Thinking at Yale. Matthew earned his PhD in Neuroscience from Yale University and his Bachelor of Sciencein Physiology from the University of British Columbia.

‍

Daisy Robinton is the Director of Women's Health at Cambrian Bio and Co-founder & CEO of Oviva Therapeutics. She was a William Randolph Hearst Postdoctoral Fellow at Harvard University focused on neuroimmunology. Dr. Robinton earned her PhD in Human Biology and Translational Medicine from Harvard University in 2016. Her discoveries elucidating the genetic intersection of stem cell identity and cancer landed her on the Forbes 30 Under 30 list in 2017. She completed her B.S. in Molecular, Cell and Developmental Biology at UCLA in 2010. Her passion for the effective translation of science has fueled her years of teaching, speaking, and consulting on numerous projects in the US and abroad. Her writing has been published in both academic journals and periodicals, including articles in Developmental Cell Nature.

Ethan Sarnoski serves as Venture Director at Cambrian Bio. Prior to joining Cambrian, he was an Engagement Manager in McKinsey & Company’s Pharmaceutical Practice. He has also worked as an Associate in Yale University’s Office of Cooperative Research. Ethan earned his PhD in Molecular Biology from Yale University, and his bachelor’s degree in Pathobiology from the University of Connecticut.

Erik Schneider is a Director of Business Development at Cambrian Bio. Previously, Erik was on the Business Development and Licensing team at Novartis, evaluating deal and portfolio strategy across cardiovascular, immunology, and neuroscience franchises. Prior to joining Novartis, Erik was a consultant at CBPartners (now Trinity Life Sciences), with a focus on commercial and pricing strategy for new products. Erik graduated from the College of the Holy Cross with a degree in Biochemistry.

‍

Orrin Stone is a Venture Director at Cambrian Bio. He was previously at BridgeBio Pharma as a Senior Director of Business Development & Operations, where he led a team responsible for sourcing and advancing new discovery programs for genetic diseases. Prior to BridgeBio, he was a consultant at McKinsey & Company, advising biopharma and private equity clients on diverse topics including clinical development and M&A. He completed a PhD at UNC Chapel Hill, where he developed new methods for quantitative analysis of cell signaling in cancer and immune disorders.

Prashant Vijay is the Vice President of New Projects at Cambrian Bio. Prashant has 20 years of experience, working at the intersection of data, technology and business, and has ideated, built and operationalized multiple products across client types and industries. Prior to joining Cambrian, Prashant was co-founder and CEO of Egregore Labs, a Natural Language Processing startup, serving clients in asset management, where he was responsible for Product Management, Business Development and Information Security.In the past, Prashant held various Management roles in Markit (acquired by S&P) covering Business Development, Product Delivery, and Account Management. Prashant started his career at Goldman Sachs in New York, where he spent close to a decade across Trading and Technology roles, focused on the North American Commodities markets. Prashant has a Bachelors of Science in Computer Science from Tulane University, and an MBA from the Indian School of Business, Hyderabad.

Ryan White serves as Senior Manager of Information Technology at Cambrian Bio. White has spent the past 13 years in various IT roles. For the past eight years, he has worked at two biopharma companies. Prior to joining Cambrian, White led the IT Service Management Program at bluebird bio, Inc. and oversaw the ServiceNow platform as part of the IT Operations team. At bluebird bio, he directed IT service management and ServiceNow platform strategy — championing high trust, secure, and compliant IT systems deployed with user functionality in mind while ensuring system alignment with business processes and people. He also supported and coached the Global End User Services team at bluebird. Before bluebird bio, White was the lead desktop support engineer at Forum Pharmaceuticals. White studied Social Thought and Political Economy at University of Massachusetts, Amherst.